{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:02:16Z","timestamp":1789560136115,"version":"build-2803163510"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-76729-4","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:20:18Z","timestamp":1786983618000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Measurable residual disease detected by next-generation sequencing in T-cell acute lymphoblastic leukemia"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7944-9411","authenticated-orcid":false,"given":"Chan","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haipin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shupeng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9164-5952","authenticated-orcid":false,"given":"Fenying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diying","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heping","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1409-5517","authenticated-orcid":false,"given":"Yongmin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1388-2535","authenticated-orcid":false,"given":"Xiaojun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"76729_CR1","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1182\/blood.2019001557","volume":"135","author":"DT Teachey","year":"2020","unstructured":"Teachey, D. T. & O\u2019Connor, D. How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children. Blood 135, 159\u2013166 (2020).","journal-title":"Blood"},{"key":"76729_CR2","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1182\/blood-2016-12-725804","volume":"129","author":"D Campana","year":"2017","unstructured":"Campana, D. & Pui, C. H. Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia. Blood 129, 1913\u20131918 (2017).","journal-title":"Blood"},{"key":"76729_CR3","doi-asserted-by":"publisher","first-page":"e346","DOI":"10.1097\/MPH.0000000000001412","volume":"41","author":"C Liao","year":"2019","unstructured":"Liao, C. et al. Minimal residual disease-guided risk restratification and therapy improves the survival of childhood acute lymphoblastic leukemia: Experience from a tertiary children\u2019s hospital in China. J. Pediatr. Hematol. Oncol. 41, e346\u2013e354 (2019).","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"76729_CR4","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.3390\/jcm10173792","volume":"10","author":"I Iacobucci","year":"2021","unstructured":"Iacobucci, I., Kimura, S. & Mullighan, C. G. Biologic and therapeutic implications of genomic alterations in acute lymphoblastic leukemia. J. Clin. Med. 10, 3792 (2021).","journal-title":"J. Clin. Med."},{"key":"76729_CR5","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/ng.3909","volume":"49","author":"Y Liu","year":"2017","unstructured":"Liu, Y. et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat. Genet. 49, 1211\u20131218 (2017).","journal-title":"Nat. Genet"},{"key":"76729_CR6","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/nrc.2016.63","volume":"16","author":"L Belver","year":"2016","unstructured":"Belver, L. & Ferrando, A. The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nat. Rev. Cancer. 16, 494\u2013507 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"76729_CR7","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1182\/blood-2016-10-706465","volume":"129","author":"T Girardi","year":"2017","unstructured":"Girardi, T., Vicente, C., Cools, J. & De Keersmaecker, K. The genetics and molecular biology of T-ALL. Blood 129, 1113\u20131123 (2017).","journal-title":"Blood"},{"key":"76729_CR8","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/s41588-022-01159-z","volume":"54","author":"SW Brady","year":"2022","unstructured":"Brady, S. W. et al. The genomic landscape of pediatric acute lymphoblastic leukemia. Nat. Genet. 54, 1376\u20131389 (2022).","journal-title":"Nat. Genet"},{"key":"76729_CR9","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1038\/s41586-024-07807-0","volume":"632","author":"P P\u00f6l\u00f6nen","year":"2024","unstructured":"P\u00f6l\u00f6nen, P. et al. The genomic basis of childhood T-lineage acute lymphoblastic leukaemia. Nature 632, 1082\u20131091 (2024).","journal-title":"Nature"},{"key":"76729_CR10","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1182\/blood.2023022920","volume":"145","author":"P P\u00f6l\u00f6nen","year":"2025","unstructured":"P\u00f6l\u00f6nen, P., Mullighan, C. G. & Teachey, D. T. Classification and risk stratification in T-lineage acute lymphoblastic leukemia. Blood 145, 1464\u20131474 (2025).","journal-title":"Blood"},{"key":"76729_CR11","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1200\/JCO.19.01692","volume":"37","author":"S Jeha","year":"2019","unstructured":"Jeha, S. et al. Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16. J. Clin. Oncol. 37, 3377\u20133391 (2019).","journal-title":"J. Clin. Oncol."},{"key":"76729_CR12","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1200\/JCO.21.02678","volume":"40","author":"DT Teachey","year":"2022","unstructured":"Teachey, D. T. et al. Children\u2019s oncology group trial AALL1231: A phase III clinical trial testing bortezomib in newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma. J. Clin. Oncol. 40, 2106\u20132118 (2022).","journal-title":"J. Clin. Oncol."},{"key":"76729_CR13","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1182\/blood.2023021184","volume":"143","author":"RJ Hayashi","year":"2024","unstructured":"Hayashi, R. J. et al. MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children\u2019s Oncology Group trial AALL1231. Blood 143, 2053\u20132058 (2024).","journal-title":"Blood"},{"key":"76729_CR14","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/bjh.12882","volume":"166","author":"K Patrick","year":"2014","unstructured":"Patrick, K. et al. Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br. J. Haematol. 166, 421\u2013424 (2014).","journal-title":"Br. J. Haematol."},{"key":"76729_CR15","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1016\/S2352-3026(15)00254-9","volume":"3","author":"V Conter","year":"2016","unstructured":"Conter, V. et al. Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis. Lancet Haematol. 3, e80\u2013e86 (2016).","journal-title":"Lancet Haematol."},{"key":"76729_CR16","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1182\/blood.2023020678","volume":"142","author":"BL Wood","year":"2023","unstructured":"Wood, B. L. et al. Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children\u2019s Oncology Group study. Blood 142, 2069\u20132078 (2023).","journal-title":"Blood"},{"key":"76729_CR17","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1111\/bjh.17424","volume":"193","author":"H Wang","year":"2021","unstructured":"Wang, H. et al. Minimal residual disease level determined by flow cytometry provides reliable risk stratification in adults with T-cell acute lymphoblastic leukaemia. Br. J. Haematol. 193, 1096\u20131104 (2021).","journal-title":"Br. J. Haematol."},{"key":"76729_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43171-9","volume":"14","author":"H Chen","year":"2023","unstructured":"Chen, H. et al. Minimal residual disease detection by next-generation sequencing of different immunoglobulin gene rearrangements in pediatric B-ALL. Nat. Commun. 14, 7468 (2023).","journal-title":"Nat. Commun."},{"key":"76729_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217104","volume":"598","author":"N Yan","year":"2024","unstructured":"Yan, N. et al. Measurable residual disease testing by next generation sequencing is more accurate compared with multiparameter flow cytometry in adults with B-cell acute lymphoblastic leukemia. Cancer Lett. 598, 217104 (2024).","journal-title":"Cancer Lett."},{"key":"76729_CR20","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1182\/blood-2015-07-655159","volume":"126","author":"M Kotrova","year":"2015","unstructured":"Kotrova, M. et al. The predictive strength of next-generation sequencing MRD detection for relapse compared with current methods in childhood ALL. Blood 126, 1045\u20131047 (2015).","journal-title":"Blood"},{"key":"76729_CR21","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1182\/blood.2022017003","volume":"141","author":"M Svaton","year":"2023","unstructured":"Svaton, M. et al. NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol. Blood 141, 529\u2013533 (2023).","journal-title":"Blood"},{"key":"76729_CR22","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1182\/blood.2023023699","volume":"144","author":"L Muffly","year":"2024","unstructured":"Muffly, L., Liang, E. C., Dolan, J. G. & Pulsipher, M. A. How I use next-generation sequencing-MRD to plan approach and prevent relapse after HCT for children and adults with ALL. Blood 144, 253\u2013261 (2024).","journal-title":"Blood"},{"key":"76729_CR23","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1038\/s41375-019-0508-7","volume":"33","author":"B Scheijen","year":"2019","unstructured":"Scheijen, B. et al. Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical feasibility study by EuroClonality-NGS. Leukemia 33, 2227\u20132240 (2019).","journal-title":"Leukemia"},{"key":"76729_CR24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40164-022-00300-2","volume":"11","author":"X Deng","year":"2022","unstructured":"Deng, X., Zhang, M., Zhou, J. & Xiao, M. Next-generation sequencing for MRD monitoring in B-lineage malignancies: from bench to bedside. Exp. Hematol. Oncol. 11, 50 (2022).","journal-title":"Exp. Hematol. Oncol."},{"key":"76729_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70193","volume":"6","author":"M Song","year":"2025","unstructured":"Song, M. et al. Minimal residual disease detection: Implications for clinical diagnosis and cancer patient treatment. MedComm (2020) 6, e70193 (2025).","journal-title":"MedComm (2020)"},{"key":"76729_CR26","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1080\/14737159.2019.1627877","volume":"19","author":"A Monter","year":"2019","unstructured":"Monter, A. & Nomded\u00e9u, J. F. ClonoSEQ assay for the detection of lymphoid malignancies. Expert Rev. Mol. Diagn. 19, 571\u2013578 (2019).","journal-title":"Expert Rev. Mol. Diagn."},{"key":"76729_CR27","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S1470-2045(15)70082-3","volume":"16","author":"CH Pui","year":"2015","unstructured":"Pui, C. H. et al. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: A prospective study. Lancet Oncol. 16, 465\u2013474 (2015).","journal-title":"Lancet Oncol."},{"key":"76729_CR28","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1182\/asheducation-2016.1.580","volume":"2016","author":"EA Raetz","year":"2016","unstructured":"Raetz, E. A. & Teachey, D. T. T-cell acute lymphoblastic leukemia. Hematol. Am. Soc. Hematol. Educ. Program 2016, 580\u2013588 (2016).","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"76729_CR29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41408-022-00606-8","volume":"12","author":"K Hein","year":"2022","unstructured":"Hein, K., Short, N., Jabbour, E. & Yilmaz, M. Clinical value of measurable residual disease in acute lymphoblastic leukemia. Blood Lymphat Cancer.12, 7\u201316 (2022).","journal-title":"Blood Lymphat Cancer"},{"key":"76729_CR30","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/ijlh.13463","volume":"43","author":"RP Correia","year":"2021","unstructured":"Correia, R. P. et al. How I investigate minimal residual disease in acute lymphoblastic leukemia. Int J. Lab Hematol. 43, 354\u2013363 (2021).","journal-title":"Int J. Lab Hematol."},{"key":"76729_CR31","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s40291-017-0277-9","volume":"21","author":"M Kotrova","year":"2017","unstructured":"Kotrova, M., Trka, J., Kneba, M. & Br\u00fcggemann, M. Is next-generation sequencing the way to go for residual disease monitoring in acute lymphoblastic leukemia. Mol. Diagn. Ther. 21, 481\u2013492 (2017).","journal-title":"Mol. Diagn. Ther."},{"key":"76729_CR32","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.3324\/haematol.2022.280638","volume":"107","author":"C Saygin","year":"2022","unstructured":"Saygin, C., Cannova, J., Stock, W. & Muffly, L. Measurable residual disease in acute lymphoblastic leukemia: Methods and clinical context in adult patients. Haematologica 107, 2783\u20132793 (2022).","journal-title":"Haematologica"},{"key":"76729_CR33","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/sj.leu.2403263","volume":"18","author":"M Br\u00fcggemann","year":"2004","unstructured":"Br\u00fcggemann, M. et al. Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia. Leukemia 18, 709\u2013719 (2004).","journal-title":"Leukemia"},{"key":"76729_CR34","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1182\/blood.V99.4.1253","volume":"99","author":"C Nyvold","year":"2002","unstructured":"Nyvold, C. et al. Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood 99, 1253\u20131258 (2002).","journal-title":"Blood"},{"key":"76729_CR35","first-page":"1126","volume":"87","author":"P Gameiro","year":"2002","unstructured":"Gameiro, P., Mortuza, F. Y., Hoffbrand, A. V. & Foroni, L. Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: A molecular based approach using T-cell receptor G and D gene rearrangements. Haematologica 87, 1126\u20131134 (2002).","journal-title":"Haematologica"},{"key":"76729_CR36","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1056\/NEJM199808273390904","volume":"339","author":"H Cav\u00e9","year":"1998","unstructured":"Cav\u00e9, H. et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group. N. Engl. J. Med. 339, 591\u2013598 (1998).","journal-title":"N. Engl. J. Med."},{"key":"76729_CR37","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/leu.2008.5","volume":"22","author":"T Flohr","year":"2008","unstructured":"Flohr, T. et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 22, 771\u2013782 (2008).","journal-title":"Leukemia"},{"key":"76729_CR38","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.3324\/haematol.2011.060426","volume":"97","author":"G Gaipa","year":"2012","unstructured":"Gaipa, G. et al. Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia. Haematologica 97, 1582\u20131593 (2012).","journal-title":"Haematologica"},{"key":"76729_CR39","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1182\/blood-2011-03-338707","volume":"118","author":"M Schrappe","year":"2011","unstructured":"Schrappe, M. et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood 118, 2077\u20132084 (2011).","journal-title":"Blood"},{"key":"76729_CR40","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.1080\/10428194.2020.1805739","volume":"61","author":"X Liu","year":"2020","unstructured":"Liu, X. et al. Minimal residual disease surveillance at day 90 predicts long-term survival in pediatric patients with T-cell acute lymphoblastic leukemia. Leuk. Lymphoma 61, 3460\u20133467 (2020).","journal-title":"Leuk. Lymphoma"},{"key":"76729_CR41","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.1182\/blood-2012-07-444042","volume":"120","author":"M Faham","year":"2012","unstructured":"Faham, M. et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood 120, 5173\u20135180 (2012).","journal-title":"Blood"},{"key":"76729_CR42","doi-asserted-by":"publisher","first-page":"134ra63","DOI":"10.1126\/scitranslmed.3003656","volume":"4","author":"D Wu","year":"2012","unstructured":"Wu, D. et al. High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia. Sci. Transl. Med. 4, 134ra63 (2012).","journal-title":"Sci. Transl. Med"},{"key":"76729_CR43","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1182\/blood-2021-152369","volume":"138","author":"JD Paolino","year":"2021","unstructured":"Paolino, J. D. et al. Performance of Next Generation Sequencing for Minimal Residual Disease Detection for Pediatric Patients with Acute Lymphoblastic Leukemia: Results from the Prospective Clinical Trial DFCI 16-001. BLOOD 138, 3485\u20133485 (2021).","journal-title":"BLOOD"},{"key":"76729_CR44","first-page":"S6","volume":"29","author":"EC Liang","year":"2023","unstructured":"Liang, E. C. et al. Trajectory of NGS MRD-detected clonotypes throughout the first year following allogeneic hematopoietic cell transplantation in adult acute lymphoblastic leukemia [abstract]. Transpl. Cell Ther. 29, S6 (2023).","journal-title":"Transpl. Cell Ther."},{"key":"76729_CR45","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jmoldx.2023.02.002","volume":"25","author":"JK Tung","year":"2023","unstructured":"Tung, J. K. et al. Minimal\/measurable residual disease monitoring in patients with lymphoid neoplasms by high-throughput sequencing of the T-cell receptor. J. Mol. Diagn. 25, 331\u2013341 (2023).","journal-title":"J. Mol. Diagn."},{"key":"76729_CR46","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1038\/s41375-019-0496-7","volume":"33","author":"M Br\u00fcggemann","year":"2019","unstructured":"Br\u00fcggemann, M. et al. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study. Leukemia 33, 2241\u20132253 (2019).","journal-title":"Leukemia"},{"key":"76729_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70206","volume":"9","author":"G Cario","year":"2025","unstructured":"Cario, G. et al. Results in pediatric T-ALL patients treated in trial AIEOP-BFM ALL 2009: Prognostic factors in the context of modern risk-adapted therapy. Hemasphere 9, e70206 (2025).","journal-title":"Hemasphere"},{"key":"76729_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07077-9","volume":"20","author":"T Ching","year":"2020","unstructured":"Ching, T. et al. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma. BMC Cancer. 20, 612 (2020).","journal-title":"BMC Cancer"},{"key":"76729_CR49","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.leukres.2012.03.014","volume":"36","author":"XJ Xu","year":"2012","unstructured":"Xu, X. J. et al. Day 22 of induction therapy is important for minimal residual disease assessment by flow cytometry in childhood acute lymphoblastic leukemia. Leuk. Res. 36, 1022\u20131027 (2012).","journal-title":"Leuk. Res"},{"key":"76729_CR50","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1038\/leu.2012.122","volume":"26","author":"T Kalina","year":"2012","unstructured":"Kalina, T. et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia 26, 1986\u20132010 (2012).","journal-title":"Leukemia"},{"key":"76729_CR51","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s12185-020-03070-x","volume":"113","author":"C Liao","year":"2021","unstructured":"Liao, C. et al. Pediatric blastic plasmacytoid dendritic cell neoplasm: report of four cases and review of literature. Int. J. Hematol. 113, 751\u2013759 (2021).","journal-title":"Int. J. Hematol."},{"key":"76729_CR52","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/978-1-62703-357-2_8","volume":"999","author":"BL Wood","year":"2013","unstructured":"Wood, B. L. Flow cytometric monitoring of residual disease in acute leukemia. Methods Mol. Biol. 999, 123\u2013136 (2013).","journal-title":"Methods Mol. Biol."},{"key":"76729_CR53","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/s41409-022-01699-2","volume":"57","author":"Y Huang","year":"2022","unstructured":"Huang, Y. et al. Predictive value of next-generation sequencing-based minimal residual disease after CAR-T cell therapy. Bone Marrow Transpl. 57, 1350\u20131353 (2022).","journal-title":"Bone Marrow Transpl."},{"key":"76729_CR54","doi-asserted-by":"publisher","first-page":"21978","DOI":"10.1002\/cam4.6771","volume":"12","author":"M Gu","year":"2023","unstructured":"Gu, M. et al. The effectiveness of blinatumomab in clearing measurable residual disease in pediatric B-cell acute lymphoblastic leukemia patients detected by next-generation sequencing. Cancer Med. 12, 21978\u201321984 (2023).","journal-title":"Cancer Med"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76729-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76729-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76729-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:03:33Z","timestamp":1789556613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76729-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["76729"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-76729-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"assertion":[{"value":"9 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"9865"}}